ArticleThe Journal of veterinary medical science2024
Establishment of new mouse model for allergic dermatitis showing severe fibrosis.
Article in The Journal of veterinary medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment of a novel murine model of allergic bronchopulmonary aspergillosis using an eosinophilic mutant mouse.The Journal of veterinary medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic dermatitis (AD) is a skin disease characterized by a chronic inflammation caused by immune dysregulation. In the histopathology of patients with AD, there are several features, such as accumulation of eosinophils and mast cells, hyperkeratosis, and dermal fibrosis which are related to the exacerbation of AD. Mast cells and eosinophils are thought to be involved in fibrosis, but the details are unknown. Yama mouse is an inbred mouse showing genetically eosinophilia. If eosinophils have significant effect on fibrosis, it may be possible to establish a new AD model with severe fibrosis. In this study, AD was induced by applying dinitrofluorobenzene to mice auricle. Yama mice showed AD lesion with more severe dermal fibrosis with severe eosinophil infiltration than Balb/c and Nc/nga mice. The expression of transforming growth factor-β (TGF-β), a cytokine important for fibrosis, was not significantly different among Yama, Balb/c, and Nc/nga mice, while the expression of interleukin-4 (IL-4), which is also mediator of tissue fibrosis, was increased only in Yama mice. The results of this study showed that AD with more severe fibrosis could be induced in Yama mice than in Balb/c and Nc/nga mice. In Yama mice, it can be concluded that the severe fibrosis is TGF-β independent, and IL-4 would be the main mediator of severe fibrosis. This mouse model may be useful for elucidating the mechanism of fibrosis in chronic AD, and for conducting research leading to the development of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.